

## Pathology Grand Rounds

Thursday, December 1st 12:30-1:30 pm

Fitkin Amphitheater - LMP 1094 (also via Zoom)

Hosted by: Manju Prasad, MBBS, MD



**Ilan Weinreb, MD, FRCP(C)**Assistant Professor of Pathology, University Health Network, Toronto, ON, Canada

Polymorphous Adenocarinoma: There and Back Again

**Needs:** The classification of salivary gland cancer has evolved considerably with the recognition of the molecular underpinnings of different cancers, thus separating tumors into separate entities and variants of those entities. In some situations this is academic, however, it may also have an impact on grading, correct diagnosis, and therapies. The classification of polymorphous adenocarcinoma remains controversial due to overlap with other entities, both on the morphologic, clinical, and molecular levels. The talk will focus on recent developments in salivary gland cancer molecular classification, with an emphasis on this controversial entity.

**Objectives:** To improve the way to obtain cytological/small samples from NSCLC patients and describe the morphologic and clinical features separating polymorphous adenocarcinoma (PAC), classical and cribriform variants.







Accreditation Statement: Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: Yale School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. Financial Disclosures: Dr. Ilan Weinreb, MD, FRCP (C), Speaker to this activity, has no financial relationships to disclose. Dr. Kurt A. Schalper, MD, PhD, faculty/planner for this educational activity is Consultant to Fee-Clinica Alemana de Santigo, Takeda, EMD Serono(relationship has ended) Merck(relationship has ended), Parthenon(relationship has ended), Sensei Therapeutics(relationship has ended) Molecular Templates, Paid Consultant-AstraZeneca, Moderna(relationship has ended), Shattuck Labs, Agennus, Honoraria-Genmab(relationship has ended))|Speaker Bureau-PeerView(relationship has ended)|Grant or research support-Astra Zeneca, Surface Oncology, Eli Lily(relationship has ended), Merck, Boehringer Ingelheim, Takeda, Akoya, GlaxoSmithKline, Ribon Therapeutics-06/14/2022. Dr. Manju Prasad, Dr. Pallavi Gopal, Damaris Battaglia, Nicole Vallati, and Samara Diggs, faculty/planners for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.